Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours

European Journal of Endocrinology

Volumn 155, Issue 2, 2006, Pages 371-379

  Hubina, Erika ^a,b   Nanzer, Alexandra M ^a   Hanson, Matthew R ^a   Ciccarelli, Enrica ^c   Losa, Marco ^e   Gaia, Daniela ^c   Papotti, Mauro ^d   Terreni, Maria Rosaria ^e   Khalaf, Sahira ^a   Jordan, Suzanne ^a   Czirják, Sándor ^f   Hanzély, Zoltán ^f   Nagy, György M ^g   Góth, Miklós I ^b   Grossman, Ashley B ^a   Korbonits, Márta ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NATIONAL MEDICAL CENTER   (Hungary)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f NATIONAL INSTITUTE OF NEUROSURGERY   (Hungary)

^g SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OCTREOTIDE; PASIREOTIDE; PROTEIN P27; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGE DISTRIBUTION; AGED; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPOPHYSIS ADENOMA; IMMUNOBLOTTING; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEX DIFFERENCE; TUMOR CELL CULTURE; TUMOR VOLUME; UPREGULATION;

ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL DIVISION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; MAP KINASE SIGNALING SYSTEM; OCTREOTIDE; PITUITARY GLAND; PITUITARY NEOPLASMS; PROLACTINOMA; RATS; SOMATOSTATIN; THYMIDINE; TRITIUM; UP-REGULATION;

EID: 33747635920     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02213     Document Type: Article

References (51)

1. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML & McCutcheon IE. The prevalence of pituitary adenomas: a systematic review. Cancer 2004 101 613-619.
2. Reubi JC & Laissue JA. Multiple actions of somatostatin in neoplastic disease. Trends in Pharmacological Sciences 1995 16 110-115.
3. Bruns C, Lewis I, Briner U, Meno-Tetang G & Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology 2002 146 707-716.
4. Weckbecker G, Briner U, Lewis I & Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/ insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002 143 4123-4130.
5. Cattaneo MG, Taylor JE, Culler MID, Nisoli E & Vicentini LM. Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells. FEBS Letters 2000 481 271-276.
6. Pages P, Benali N, Saint-Laurent N, Esteve JP, Schally AV, Tkaczuk J, Vaysse N, Susini C & Buscail L. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. Journal of Biological Chemistry 1999 274 15186-15193.
7. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994 78 59-66.
8. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I & Loh DY. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996 85 707-720.
9. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA & Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996 85 721-732.
10. Fero ML, Rivkin M, Tasch M, Porter F, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V Perlmutter RM, Kaushansky K & Roberts JM. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996 85 733-744.
11. Kip1 in human pituitary adenomas. European Journal of Endocrinology 1999 140 250-255.
12. Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1999 84 3823-3830.
13. Qian X, Jin L, Grande JP & Lloyd RV. Transforming growth factor-beta and p27 expression in pituitary cells. Endocrinology 1996 137 3051-3060.
14. Theodoropoulou M, Arzberger T, Gruebler Y, Jaffrain-Rea ML, Schlegel J, Schaaf L, Petrangeli E, Losa M, Stalla GK & Pagotto U. Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma. cells. Journal of Endocrinology 2004 183 385-394.
15. Komatsubara K, Tahara S, Umeoka K, Sanno N, Teramoto A & Osamura RY. Immunohistochemical analysis of p27 (Kip1) in human pituitary glands and in various types of pituitary adenomas. Endocrine Pathology 2001 12 181-188.
16. Takeuchi S, Koeffler HP, Hinton DR, Miyoshi I, Melmed S & Shimon I. Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors. Journal of Endocrinology 1998 157 337-341.
17. Nanzer AM, Khalaf S, Mozid AM, Fowkes RC, Patel MV, Burrin JM, Grossman AB & Korbonits M. Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. European Journal of Endocrinology 2004 151 233-240.
18. Korbonits M, Chitnis MM, Gueorguiev M, Norman D, Rosenfelder N, Suliman M, Jones TH, Noonan K, Fabbri A, Besser GM, Burrin JM & Grossman AB. The release of leptin and its effect on hormone release from human pituitary adenomas. Clinical Endocrinology 2001 54 781-789.
19. Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, Papotti M, Mangili F, Terreni MR, Camanni F & Giovanelli M. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2001 86 5194-5200.
20. Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1999 84 3823-3830.
21. Kip1 protein and Jab 1 (Jun activation domain-binding protein 1) in human pituitary tumors. Journal of Clinical Endocrinology and Metabolism 2002 87 2635-2643.
22. Qian X, Jin L, Kulig E & Lloyd RV. DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. American Journal of Pathology 1998 153 1475-1482.
23. Florio T, Thellung S, Arena S, Corsaro A, Spaziante R, Gussoni G, Acuto G, Giusti M, Giordano G & Schettini G. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. European Journal of Endocrinology 1999 141 396-408.
24. Renner U, Mojto J, Lange M, Muller OA, von Werder K & Stalla GK. Effect of bromocriptine and SMS 201-995 on growth of human somatotrophic and non-functioning pituitary adenoma cells in vitro. European Journal of Endocrinology 1994 130 80-91.
25. Cheung NW & Boyages SC. Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block. Endocrinology 1995 136 4174-4181.
26. Kip1 protein and Jab1 (Jun activation domain-binding protein 1) in human pituitary tumors. Journal of Clinical Endocrinology and Metabolism 2002 87 2635-2643.
27. Kip1. Endocrinology 1999 140 87-95.
28. Fisher WE, Wu Y, Amaya F & Berger DIL Somatostatin receptor subtype 2 gene therapy inhibits pancreatic cancer in vitro. Journal of Surgical Research 2002 105 58-64.
29. Celinski SA, Fisher WE, Amaya F, Wu YQ, Yao Q, Youker KA & Li M. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts. Journal of Surgical Research 2003 115 41-47.
30. Benali N, Ferjoux G, Puente E, Buscail L & Susini C. Somatostatin receptors. Digestion 2000 62 (Suppl 1) 27-32.
31. Buscail L, Esteve JF, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, Bell GI, Schally AV, Vaysse N & Susini C. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. PNAS 1995 92 1580-1584.
32. Reubi JC, Lang W, Maurer R, Koper JW & Lamberts SW. Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Research 1987 47 5758-5764.
33. Zhu JS, Wang L, Cheng GQ, Li Q, Zhu ZM & Zhu L. Apoptosis mechanisms of human gastric cancer cell line MKN-45 infected with human mutant p27. World Journal of Gastroenterology 2005 11 7536-7540.
34. The odoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U & Stalla GK. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Research 2006 66 1576-1582.
35. Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Bruns C & Melmed S. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. Journal of Clinical Endocrinology and Metabolism 2004 89 3027-3032.
36. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A & Lamberts SW. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 2004 89 1577-1585.
37. van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW & Holland LJ. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumour cells. American Journal of Physiology-Endocrinology and Metabolism 2005 289 E278-E287.
38. Silva AP, Bethmann K, Raul F & Schmid HA. Regulation of ghrelin secretion by somatostatin analogs in rats. European Journal of Endocrinology 2005 152 887-894.
39. van der Hoek J, de Herder WW Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Peon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ & Lamberts SW. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. Journal of Clinical Endocrinology and Metabolism 2004 89 638-645.
40. Ma P, Wang Y, van der HJ, Nedelman J, Schran H, Tran LL & Lamberts SW. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clinical Pharmacology and Therapy 2005 78 69-80.
41. Jaquet P, Saveanu A, Gunz G, Fina E, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A & Ouafik LH. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. Journal of Clinical Endocrinology and Metabolism 2000 85 781-792.
42. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC & Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. Journal of Biological Chemistry 2000 275 7862-7869.
43. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC & Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000 288 154-157.
44. Reisine T & Bell GI. Molecular biology of somatostatin receptors. Endocrine Reviews 1995 16 427-442.
45. Adams RL, Adams IP, Lindow SW & Atkin SL. Inhibition of endothelial proliferation by the somatostatin analogue SOM230. Clinical Endocrinology 2004 61 431-436.
46. Patel YC. Somatostatin and its receptor family. Frontiers of Neuroendocrinology 1999 20 157-198.
47. Lamberts SWJ, van der Lely AJ, deHerder WW & Hofland LJ. Octreotide. New England Journal of Medicine 1996 334 246-254.
48. Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 1856-1863.
49. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC & Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocrine Reviews 1999 17 610-638.
50. Colao A, Filippella M, Di Somma C, Manzi S, Rota F, Pivonello R, Gaccione M, De Rosa M & Lombardi G. Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas. Endocrine 2003 20 279-283.
51. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A & Santoro M. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nature Medicine 2002 8 1136-1144.